ObsEva SA (OBSV) Stock
OBSV is no longer traded. ObsEva was delisted from the Nasdaq in April 2023.
Prices on this page are historical; the last trade was April 24, 2023 at $0.08.
ObsEva stock price history
OBSV final trading statistics
- Final close
- $0.08
- Final trading day
- Apr 24, 2023
- Market cap at delisting
- $9.07M
- Shares outstanding
- 108.02M
- Final 52-week range
- $0.07 – $2.14
- Avg. volume (final 3 mo.)
- 7,788,691
- All-time high (split-adj.)
- $18.18 · Sep 2018
- All-time low (split-adj.)
- $0.08 · Mar 2023
- Return since IPO
- -99.4%
- Beta
- 0.67
- Book value / share
- -$0.03
- Price / book
- -2.80
ObsEva annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $19.64M | -$29.9M | -$0.41 |
| FY2021 | $0.00 | -$58.4M | -$0.79 |
| FY2020 | $0.00 | -$83.0M | -$1.67 |
| FY2019 | $0.00 | -$108.8M | -$2.50 |
| FY2018 | $0.00 | -$76.7M | -$1.91 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About ObsEva SA
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
ObsEva stock FAQ
What happened to ObsEva stock?
ObsEva stock was delisted from the Nasdaq. Its final close was $0.08 on April 24, 2023.
Is OBSV stock still trading?
No. OBSV was delisted from the Nasdaq in April 2023 and no longer trades on a U.S. exchange.
What was the last price of OBSV stock?
OBSV closed at $0.08 on its final trading day, April 24, 2023, for a market value of about $9.07M.
What were ObsEva's revenue and earnings in its last full fiscal year?
ObsEva reported revenue of $19.64M and net income of -$29.9M in fiscal 2022, its last full year as a public company.
When did ObsEva go public?
ObsEva SA stock began trading on January 26, 2017.